The use of cognitive behavioral therapy in the treatment of depression in patients with Parkinson's disease: an integrative review
DOI:
https://doi.org/10.25118/2763-9037.2024.v14.1282Keywords:
Parkinson disease, depression, cognitive behavioral therapyAbstract
Introduction: Parkinson's disease (PD) is a neurodegenerative condition characterized by black substance degeneration and is associated with debilitating motor and non-motor complications. The emergence of depressive symptoms sometimes precedes motor symptoms, and can be characterized as the first signs of PD. The application of pharmacological therapy through the use of antidepressants in patients affected by depression on PD is frequently reported. Meanwhile, non-pharmacological therapies can be integrated into the therapeutic protocol, logo, or objective of this study to investigate the applicability and viability of cognitive-behavioral therapy, considering both the in-person modality and the telehealth approaches. Methods: This is an integrative literature review based on the Whittemore and Knafl method, which is not configured as a research method that makes it possible to synthesize and analyze what exists in the production of cognitive behavioral therapy in the treatment of depression in patients with Parkinson's disease. Results: In this study, we carried out an integrative review on the effectiveness of cognitive-behavioral therapy (CBT) in the treatment of depression in patients with Parkinson's disease (PD). We note that, while some studies suggest additional benefits when CBT is combined with medications, there is interest in investigating its isolated effectiveness. Different scales are used to assess depressive symptoms, highlighting Hamilton's Depression Assessment Scale. Some interventions include sound strategies to improve overall well-being. Notably, the methodology varied between studies, with some opting for virtual interventions, or showing a lower dropout rate. Conclusion: In summary, our review highlights the effectiveness of cognitive-behavioral therapy (CBT) in the treatment of depression in patients with Parkinson's Disease (DP). Although the combination of medications seems promising, our results indicate that isolated CBT can also be beneficial. However, we suggest additional research focused on virtual interventions, aiming to improve accessibility and adequacy of treatment for this population.
Downloads
Metrics
References
Shinmei I, Kobayashi K, Oe Y, Takagishi Y, Kanie A, Ito M, Takebayashi Y, Murata M, Horikoshi M, Dobkin RD. Cognitive behavioral therapy for depression in Japanese Parkinson's disease patients: a pilot study. Neuropsychiatr Dis Treat. 2016;12:1319-31. https://doi.org/10.2147/NDT.S104777 PMID:27354802 - PMCID:PMC4908947 DOI: https://doi.org/10.2147/NDT.S104777
Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman J. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066-74. https://doi.org/10.1176/appi.ajp.2011.10111669 - PMID:21676990 PMCID:PMC3186855 DOI: https://doi.org/10.1176/appi.ajp.2011.10111669
Ryman SG, Poston KL. MRI biomarkers of motor and non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2020;73:85-93. https://doi.org/10.1016/j.parkreldis.2019.10.002 PMID:31629653 - PMCID:PMC7145760 DOI: https://doi.org/10.1016/j.parkreldis.2019.10.002
Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson's disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134:104700. https://doi.org/10.1016/j.nbd.2019.104700 - PMID:31809788 DOI: https://doi.org/10.1016/j.nbd.2019.104700
Dobkin RD, Mann SL, Interian A, Gara MA, Menza M. Cognitive behavioral therapy improves diverse profiles of depressive symptoms in Parkinson's disease. Int J Geriatr Psychiatry. 2019;34(5):722-9. https://doi.org/10.1002/gps.5077 PMID:30714202 DOI: https://doi.org/10.1002/gps.5077
Ahmad MH, Rizvi MA, Ali M, Mondal AC. Neurobiology of depression in Parkinson's disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing Res Rev. 2023;85:101840. https://doi.org/10.1016/j.arr.2022.101840 PMID: 36603690. DOI: https://doi.org/10.1016/j.arr.2022.101840
Dobkin RD, Mann SL, Gara MA, Interian A, Rodriguez KM, Menza M. Telephone-based cognitive behavioral therapy for depression in Parkinson disease: a randomized controlled trial. Neurology. 2020;94(16):e1764-e1773. https://doi.org/10.1212/WNL.0000000000009292 - PMID:32238507 PMCID:PMC7282876 DOI: https://doi.org/10.1212/WNL.0000000000009292
Dobkin RD, Allen LA, Menza M. Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study. Mov Disord. 2007;22(7):946-52. https://doi.org/10.1002/mds.21455 PMID:17377926 DOI: https://doi.org/10.1002/mds.21455
Piers RJ, Farchione TJ, Wong B, Rosellini AJ, Cronin-Golomb A. Telehealth tansdiagnostic cognitive behavioral therapy for depression in Parkinson's disease: a pilot randomized controlled trial. Mov Disord Clin Pract. 2023;10(1):79-85. https://doi.org/10.1002/mdc3.13587 PMID:36704072 PMCID:PMC9847300 DOI: https://doi.org/10.1002/mdc3.13587
Santos CMC, Pimenta CAM, Nobre MRC. The PICO strategy for the research question construction and evidence search. Rev Latino-Am Enfermagem. 2007;15(3):508–11. https://doi.org/10.1590/S0104-11692007000300023 DOI: https://doi.org/10.1590/S0104-11692007000300023
Dobkin RD, Mann SL, Weintraub D, Rodriguez KM, Miller RB, St Hill L, King A, Gara MA, Interian A. Innovating Parkinson's care: a randomized controlled trial of telemedicine depression treatment. Mov Disord. 2021;36(11):2549-58. http://doi.org/10.1002/mds.28548 - PMID: 33710659 DOI: https://doi.org/10.1002/mds.28548
Dobkin RD, Allen la, Menza M. A cognitive-behavioral treatment package for depression in Parkinson's disease. Psychosomatics. 2006;47(3):259-63. https://doi.org/10.1176/appi.psy.47.3.259 DOI: https://doi.org/10.1176/appi.psy.47.3.259
Calleo JS, Amspoker AB, Sarwar AI, Kunik ME, Jankovic J, Marsh L, York M, Stanley MA. A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease. J Geriatr Psychiatry Neurol. 2015;28(3):210-7. https://doi.org/10.1177/0891988715588831 - PMID:26047635 DOI: https://doi.org/10.1177/0891988715588831
Troeung L, Egan SJ, Gasson N. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson's disease. BMC Psychiatry. 2014;14:19. https://doi.org/10.1186/1471-244X-14-19 - PMID:24467781 PMCID:PMC3907935 DOI: https://doi.org/10.1186/1471-244X-14-19
Wuthrich VM, Rapee RM. Telephone-delivered cognitive behavioural therapy for treating symptoms of anxiety and depression in Parkinson's disease: a pilot trial. Clin Gerontol. 2019;42(4):444-53. https://doi.org/10.1080/07317115.2019.1580811 PMID:30821649 DOI: https://doi.org/10.1080/07317115.2019.1580811
Veazey C, Cook KF, Stanley M, Lai EC, Kunik ME. Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease. J Clin Psychol Med Settings. 2009;16(3):243-53. https://doi.org/10.1007/s10880-009-9167-6 - PMID:19404724 DOI: https://doi.org/10.1007/s10880-009-9167-6
Published
How to Cite
Conference Proceedings Volume
Section
License
Copyright (c) 2024 Bianca Araujo Vieira, Alexandre Almeida da Silva, Júlio César Claudino dos Santos
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Debates em Psiquiatria allows the author (s) to keep their copyrights unrestricted. Allows the author (s) to retain their publication rights without restriction. Authors should ensure that the article is an original work without fabrication, fraud or plagiarism; does not infringe any copyright or right of ownership of any third party. Authors should also ensure that each one complies with the authorship requirements as recommended by the ICMJE and understand that if the article or part of it is flawed or fraudulent, each author shares responsibility.
Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) - Debates em Psiquiatria is governed by the licencse CC-By-NC
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
